OCEA
NASDAQOcean Biomedical Inc.
Price$0.02+0.00 (+0.00%)
2026-01-162026-04-22
Latest news
25 items- SECSEC Form NT 10-Q filed by Ocean Biomedical Inc.NT 10-Q - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECSEC Form 25-NSE filed by Ocean Biomedical Inc.25-NSE - Ocean Biomedical, Inc. (0001869974) (Subject)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECSEC Form 10-Q filed by Ocean Biomedical Inc.10-Q - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Ocean Biomedical Inc.10-K/A - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- PROcean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder ValueStrategic diversification into power infrastructure and cryptocurrencies supports long-term biopharma innovation PROVIDENCE, R.I., April 22, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company focused on pioneering treatments for cancer, infectious diseases, and fibrosis, today announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana. This move comes as part of a deliberate plan to strengthen Ocean Biomedical's financial foundation and enhance long-term value creation for shareholders. The Company will leverage its leadership team's exp
- SECSEC Form 10-K filed by Ocean Biomedical Inc.10-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECSEC Form NT 10-K filed by Ocean Biomedical Inc.NT 10-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- PROcean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaPROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic a
- SECOcean Biomedical Inc. filed SEC Form 8-K: Other Events8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECSEC Form DEFA14A filed by Ocean Biomedical Inc.DEFA14A - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Leadership Update8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECSEC Form DEF 14A filed by Ocean Biomedical Inc.DEF 14A - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECSEC Form PRE 14A filed by Ocean Biomedical Inc.PRE 14A - Ocean Biomedical, Inc. (0001869974) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ocean Biomedical Inc.SCHEDULE 13G/A - Ocean Biomedical, Inc. (0001869974) (Subject)
- SECOcean Biomedical Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
- PROcean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage DevelopmentCompany Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) today announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean's immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper's findings demonstrate that its proprietary cancer immunothe
OCEA FAQ
5 questionsWhere does OCEA stock trade?
Ocean Biomedical Inc. (OCEA) is listed on NASDAQ.What sector and industry is OCEA in?
Ocean Biomedical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ocean Biomedical Inc. go public?
Ocean Biomedical Inc. (OCEA) completed its IPO in 2021.What companies are similar to OCEA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OCEA side-by-side with any of them on Quantisnow.How can I track OCEA on Quantisnow?
Quantisnow aggregates Ocean Biomedical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCEA to receive live email and push alerts on every new disclosure.